Adamis up as dosing begins in COVID-19 treatment study

DMK Pharmaceuticals

02/09/2021 13:11

** Shares of drug developer  ADMP.O  rise 3.6% to $1.15
premarket
    ** Co starts dosing patients in a mid-to-late-stage trial to
test its oral antiviral drug, Tempol, in COVID-19
patients urn:newsml:reuters.com:*:nGNX1SX2gW
    ** Trial will evaluate rate of hospitalization for patients
receiving Tempol, versus those receiving placebo
    ** 248 high risk unvaccinated adult subjects with early
COVID-19 infection will be enrolled in the study
    ** In August, ADMP said data from a study which tested
effects of Tempol on immune cells of COVID-19 patients showed
the drug has strong in-vitro anti-cytokine activity  urn:newsml:reuters.com:*:nL4N2PV3BW
    ** Co has worldwide license to use Tempol to treat
respiratory diseases including asthma and influenza, among other
conditions
    ** Stock has more than doubled YTD

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))